Webinar Overview
Updates to REACH for endocrine disruptor testing were initially expected in 2022 – however, multiple delays have pushed the expected release to the end of 2023, at the earliest. Repeated delays are causing uncertainty in the chemical industries, so you may be hesitant to commit to development and registration programs which may not seem future proof.
The new CLP hazard classes for endocrine disruptors are now in place, and the first deadlines for compliance have been set for 2025. Our regulatory and endocrine disruptor experts discuss what is currently known, unknown, and predicted globally for endocrine disruptor testing.
View this webinar to help you and your team:
- Gain insights into potential REACH updates
- Hear how these updates could impact global regions
- Learn about challenges faced by industry players and solutions we have provided
This will be followed by a live Q&A session, where our experts can answer your endocrine disruptor questions.
Webinar Presenters
Ilse Tonk, PhD, ERT
Senior Principal Regulatory Toxicologist
Charles River
Mira Wenker, PhD
Section Head, Drug Metabolism and Pharmacokinetics
Charles River